Docetaxel (T) and mitomycin C (M) as second-line treatment in advanced non-small-cell lung cancer (NSCLC). Results of a phase II study of the ONCOPAZ Cooperative Group

7337 Background: Single-agent T represents the standard treatment in NSCLC patients recurring after first-line chemotherapy. The aim was to evaluate whether T in combination with M would lead to an improved outcome with similar toxicity and increased efficacy compared to T monotherapy as second-line chemotherapy in NSCLC. Methods: Patients (pts), aged ≥18 years, with histopathological diagnosis of NSCLC with progression after first-line chemotherapy, measurable disease, ECOG < 2 and adequate bone marrow, renal and hepatic functions were included in this study. T was administered iv at 75 mg/m2 followed by M at 8 mg/m2 both on day 1, every 21 days. Results: A total of 49 pts: male/female, 41/8; median age 57 years (36–74), ECOG PS 0/1: 31%/69%. Tumor sites were lung (n=42) and mediastinum (n=7). Median number of metastatic sites was 1 located in nodes (39%), bone (29%) and adrenal (22%). Tumor histology included adenocarcinoma (43%), squamous cell (33%) and large cell (25%). A total of 230 cycles have been...